Background: Schizophrenia (SCZ) and depression (MDD) are associated with changes in sleep and activity patterns. However, because of a lack of objective evaluation, the diagnostic or clinical value of these sleep-activity patterns is unknown. In this study, we attempted to assess and compare the sleep and activity patterns using actigraphy. Materials and Methods: We have recruited 35 patients with SCZ (mean age: 29.29 ± 7.54 years) and 42 patients with MDD (mean age: 27.5 ± 5.59 years) in this cross-sectional study. The actigraphy indices [Time in bed (minutes), Onset latency (minutes), Total sleep time (Minutes), Sleep efficiency (%), WASO (minutes), number of awakening, and activity duration (minutes) were compared among the two groups using unpaired t -test and Fisher exact test. Results: In the MDD group, the time in bed (minutes) was significantly higher than in the SCZ group (402.7 ± 41.97 vs. 379.1 ± 40.45, P = 0.01), while the sleep efficiency was lower in the SCZ group than in the MDD group (60.04 ± 9.25 vs. 65.05 ± 7.16, P = 0.0092). An increase in onset latency (minutes) was observed in the SCZ group compared to the MDD group (49.06 ± 16.09 vs. 43.6 ± 10.14, P = 0.074). The difference in WASO (minutes), the number of awakenings, and activity duration (minutes) among the two groups were insignificant. Conclusion: Actigraphy parameters such as sleep efficiency and time in bed may be a useful sleep process, etiological, and prognostic markers in patients with SCZ and MDD. The longitudinal studies are needed to estimate the predictive role of these parameters for therapeutic outcome in these patients.

Background: Memory dysfunction, deficits in attention and executive functions as well impairment in cognition is found among patient suffering from Schizophrenia and Mood Disorder throughout the course of illness. All these significantly impact various domains of life in them. It also affects the patient’s insight into the illness and thus impairs therapeutic compliance. Objectives: To evaluate Cognitive functions in patients with Schizophrenia and Mood Disorder. To compare both groups to see whether cognitive dysfunction varies between them. Methodology: Study Design: Cross-sectional study which is Hospital-based. Study-Setting: The IPD and OPD of Psychiatry Department, AVBRH, Sawangi (M), Wardha. Sample Size: 240 (120 patients with Schizophrenia and Mood Disorder each). Patients clinically diagnosed having Schizophrenia and Mood disorder using ICD-10 criteria of age group 18-55 years, with at least 8 years of schooling will be included in the study after taking written informed consents. After collecting socio-demographic data and screening the patients with the Brief Psychiatric Rating Scale, the PGI Battery of Brain Dysfunction will be applied to the patients. Results: This study will assess of impairment of Cognitive functions Schizophrenia as well as Mood Disorder patients would tell whether the cognitive impairment is the same or different in both groups. Conclusion: Comparison of impairment in cognitive functions in Schizophrenia as well as Mood Disorder patients would be done. Co-relation of Cognitive impairment with Metabolic syndrome in both groups can be established.